National Bank of Canada
KRTX

National Bank of Canada’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

National Bank of Canada’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-128
Closed -$20.8K – 2929
2023
Q3 		$20.8K Buy
128
+18
+16% +$3.38K ﹤0.01% 2028
2023
Q2 		$23.9K Buy
110
+10
+10% +$2.14K ﹤0.01% 1970
2023
Q1 		$18.2K Sell
100
-1
-1% -$191 ﹤0.01% 1995
2022
Q4 		$19.8K Buy
+101
New +$21.7K ﹤0.01% 2000

Other funds holding KRTX

Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

National Bank of Canada's KRTX Position: Q4 2023 in Review

National Bank of Canada sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q4 2023, closing a stake of 128 shares — an estimated $20.8K sold.

National Bank of Canada first reported a position in KRTX in Q4 2022 and held it in 4 quarters. The position peaked at $23.9K in Q2 2023. 328 funds tracked by Wall St. Rank hold KRTX as of Q4 2023.

  • National Bank of Canada reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • National Bank of Canada sold 128 Karuna Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $20.8K.
  • National Bank of Canada first reported a position in Karuna Therapeutics, Inc. Common Stock in Q4 2022 and held it in 4 quarters.
  • National Bank of Canada's Karuna Therapeutics, Inc. Common Stock position peaked at $23.9K in Q2 2023.
  • 328 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q4 2023.

Based on National Bank of Canada's 13F filing for Q4 2023, filed 6 Feb 2024.